This study is looking for a better way to find if colorectal cancer (cancer that starts in the colon or rectum) that has spread to the liver has also spread to other parts of the body (extrahepatic metastasis). Currently, imaging tests sometimes miss these small or hidden cancer spots. Researchers are testing a new method called EXELION, which looks at tiny particles called exosomes in your blood. These exosomes contain microRNA, which can show how cancer is behaving. The goal is to see if EXELION can find these extra cancer spots more accurately than current methods. You may be able to join if you are an adult with confirmed metastatic colorectal cancer, have pre-treatment blood samples available, and have enough medical information to know if you have extrahepatic metastasis. The main goal is to see how well EXELION can detect these extra cancer spots.

Study design

This is an observational study, meaning participants are not given a specific treatment but are observed. It aims to enroll 500 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, sensitivity, will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.